Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC
CAMBRIDGE, Mass., Dec. 30, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH)…
U.S. FDA Approves Agios AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and…
Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor
CAMBRIDGE, Mass., Dec. 19, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH)…
Cambridge Mobile Telematics Receives Frost & Sullivan’s 2025 Global Telematics Insurance and Connected Claims Market Leadership Recognition for Excellence in Mobility Ecosystem Innovation
CMT is honored for advancing crash technology and shaping the future of…
Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods
BRISBANE, Australia and CAMBRIDGE, Mass., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Australian…
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
CAMBRIDGE, Mass., Dec. 9, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) today…
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
December 09, 2025 21:50 ET | Source: Wave Life Sciences USA, Inc.…
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9…
Eisai Submits New Drug Application for Subcutaneous Formulation of LEQEMBI for the Treatment of Early Alzheimers Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in…
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Cypherpunk Technologies Inc., previously known as…